|
This photo has nothing to do with Hydrea;
I just want to show off my cat, Flora, who
is pretty, affectionate, and well behaved,
but does not want to pose for pictures.
|
This month I have my quarterly CBC test. At my March test, my platelets were up about 100 points, to 735; if they've risen, I'll need to contact my hematologist to see about starting hydroxyurea (Hydrea).
In getting myself prepared for the possibility of starting oral chemo, my first question is: How well does it work in reducing platelet counts that contribute to blood clots, the main danger with ET?
That question was answered 20 years ago in an article in the New England Journal of Medicine. Researchers followed 114 ET patients for a little over two years. They found that, among the control group (those taking no Hydrea), the incidence of a clot was about 24 percent. In the group taking Hydrea, the incidence was about 3 percent. The platelet count for those taking Hydrea stayed around 600. Those not on Hydrea had blood counts that varied between about 450 to 1.5 million.
Only 4 patients developed bleeding, just one was in the Hydrea group.
So, yup, it works, and that's why Hydrea remains the go-to drug for patients with ET.